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INTRODUCTION 
TUBERCULOSIS 
Tuberculosis is a contagious disease caused by bacteria called Mycobacterium 
tuberculosis and it is an air borne disease. Tuberculosis generally affects the lungs, but 
can also affect the other parts of the body. Tuberculosis is spread through the air when 
people who have active TB in their lungs cough, spit, speak, or sneeze. People with 
latent TB do not spread the disease. Active infection occurs more often in people with 
HIV/AIDS and in those who smoke. Tuberculosis is curable and preventable disease.
 [1]
 
BACKGROUND  
Tuberculosis is the second most deadly disease (first HIV/AIDS) and continues to 
be a major worldwide problem. According to the World health Organization (WHO) 
about one-third of the World’s population has latent TB. The WHO also declared that TB 
is only second to HIV/AIDS as the most dreaded disease. In 2015, 10.4 million people 
fell ill with TB disease and 1.8 million people died from TB (including 0.4 million 
among people with HIV). Over 95% of TB deaths occur in low and middle income 
countries. 
In 2015, an estimated 1 million children became ill with TB and 1, 70,000 
children died of TB (excluding children with HIV). Globally in 2015, an estimated 
4,80,000 people developed multidrug- resistant TB (MDR-TB).TB incidence has 
fallen by an average of 1.5% per year since 2000.This needs to accelerate to a 4-5% 
annual decline to reach the 2020 milestone of the “END TB STRATEGY”. Ending 
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the TB epidemic by 2030 is among the health targets of the newly adopted 
Sustainable Development Goals.
 [2]
 
HISTORY
 [3]
 
M. Tuberculosis, then known as the “Tubercle Bacillus”, was first described on 
24 march1882 by Robert Koch, who subsequently received the Nobel Prize in 
physiology or medicine for this discovery in 1905. Tuberculosis has existed throughout 
history, but the name has changed frequently over time. As the Physician Benjamin 
Marten described in his “A Theory of Consumption”, Tuberculosis may be caused by 
small living creatures transmitted through the air to other persons. The historical term 
"consumption" came about due to the weight loss. 
M. tuberculosis is carried in airborne particles, called droplet nuclei, of 1– 5 
microns in diameter. Infectious droplet nuclei are generated when persons who have 
pulmonary or laryngeal TB disease cough, sneeze, shout, or sing. Depending on the 
environment, these tiny particles can remain suspended in the air for several hours. M. 
tuberculosis is transmitted through the air, not by surface contact. Transmission occurs 
when a person inhales droplet nuclei containing M. tuberculosis, and the droplet nuclei 
traverses the mouth or nasal passages, upper respiratory tract,  bronchi to reach the 
alveoli of the lungs.
 [4]
 
MYCOBACTERIA 
                 Mycobacterium Tuberculosis is a pathogenic bacterial species of the family 
mycobacteriaceae and the causative agent of most cases of TB. M. Tuberculosis is the 
rod- shaped, spore forming aerobic bacterium. Mycobacterium typically measure 0.5µm 
to 3µm, are classified as acid fast bacilli and have an unusual waxy coating on their cell 
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surface (Primarily due to the presence of mycolic acid).  The Ziehl- neelsen or acid fast 
stain is used.   
TYPES OF TUBERCULOSIS  
 Active tuberculosis  
 Latent  tuberculosis  
 
ACTIVE TUBERCULOSIS  
          Active tuberculosis means the bacteria are active in the body i.e., the immune 
system is unable to stop these bacteria from causing illness. 
LATENT TUBERCULOSIS 
It is also known as inactive TB. If a person has a latent TB, their body has been 
able to successfully fight against the bacteria and stop them from causing illness. People 
who have latent TB do not feel sick, do not have symptoms and cannot spread 
tuberculosis. In the people who have HIV, the inactive TB may become active TB if their 
immune system becomes weakened.
 [5]
 
 
Figure 1
[6] 
INTRODUCTION 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY Page 4 
 
 
MYCOBACTERIAL CELL WALL 
Mycobacterium Tuberculosis has a tough cell wall that prevents passage of 
nutrients and therefore giving it the characteristic of slow growth rate. The cell wall of 
the pathogen looks like a gram- positive cell wall. The cell envelop contains a 
polypeptide layer, a peptidoglycan layer, and free lipids. It also contains complex 
structure of fatty acids such as mycolic acid that appear glossy. The Mycobacterium 
tuberculosis cell wall contains three classes of mycolic acids: Alpha, keto, and methoxy 
mycolates. The cell wall contains lipid complexes including acyl glycolipids and 
sulfolipids. These are porins in the membranes to facilitate transport. Beneath the cell 
wall there are layer of arabinogalactone and peptidoglycan that lie just above the plasma 
membrane. .
 [7]
 
 
                       Figure 2
[8]
 MYCOBACTERIAL CELL WALL 
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GENOME 
The mycobacterium tuberculosis genome encodes about 190 transcriptional 
regulators, including sigma factors, two- components system and more than 140 
transcription regulators. Several regulators have been found to environmental distress, 
such as extreme cold or heat, iron starvation and oxidative stress. To survive in these 
harsh conditions for a long period in the host, Mycobactrerium Tuberculosis has learnt to 
adapt to the environment by allowing an inhibiting transcription according to its 
surrounding. 
[9]
 
GENOME STRUCTURE 
 Mycobacterium Tuberculosis has circular chromosomes of   about 4,200,000 
long nucleotide.
 [10]
 The genome was studied generally using the strain Mycobacterium 
tuberculosis H37RV. The genome comprises 4,411,529 base pairs, contains around 4,000 
genes, and has a very high guanine + cytosine content that is reflected in the biased 
amino-acid content of the proteins. Genes that code for lipid metabolism are very 
important part of the bacterial genome and 8% of the genome is involved in its 
activity.
[11] 
Plasmids are also important in transferring virulence because genes on the plasmids are 
more easily transferred than genes located on the chromosome. One such 18kb plasmid 
in the mycobaterium tuberculosis H37RV strain was proven to conduct gene transfer.
 [12]
 
CHOLESTEROL METABOLISM 
            Cholesterol metabolism has been studied exclusively because of its possible 
therapeutic applications in TB infections. It has been shown numerous times that TB 
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requires cholesterol for virulence in vivo, because mycobacterium tuberculosis the 
causative agent utilizes cholesterol as a source of carbon, energy, and steroid-derived 
metabolites throughout the course of infection.
 [13]
 
ROLE OF CHOLESTEROL IN TB INFECTION 
             Tuberculosis infection has unique virulence factors compared to most pathogens. 
They infect host cell and persist inside phagosome, where there are limited nutrients. 
Tuberculosis has ability to utilize cholesterol, which is a common component of human 
cell membrane, plays a role in its persistence,
 [7]
 because the cholesterol catabolism 
pathway requires oxygen that TB infect the lungs where oxygen concentrations are 
high.
[14]
 
PATHOPHYSIOLOGY
 
FIGURE 3[15] 
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LIFECYCLE OF MYCOBACTERIUM TUBERCULOSIS [16]  
The five Stages of Tuberculosis  
1) Onset (1-7 Days): The Bacteria is inhaled.  
2) Symbiosis (7-21 Days): If the Bacteria does not get killed then it reproduces.  
3) Initial Caseous Necrosis (14-21 Days): Tuberculosis starts to develop when the 
Bacteria slows down at reproducing; they kill the surrounding non activated 
Macrophages and run out of cells to divide in. The Bacteria then produces anoxic 
conditions and reduces the P
H
. The Bacteria can't reproduce anymore but can live for a 
long time.  
4) Interplay of Tissue Damaging and Macrophage Activating Immune Response 
(After 21 days): Macrophages surround the tubercle but some may be inactive. 
Tuberculosis then uses it to reproduce which causes it to grow. The tubercle can break 
off and spread around. If it spreads in the blood one can develop tuberculosis outside the 
lungs, this is called Miliary Tuberculosis.  
5) Liquification and Cavity Formation: The tubercles at one point will liquefy, which will 
make the disease spread faster, not everyone will get to this stage. Only a small percent of 
people will get to this stage. 
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FIGURE 4[17] 
     
TB treatment
 [18]
 
The aims of TB treatment are: 
 To cure the patient of TB and restore their quality of life and productivity; 
 To prevent relapse of TB; 
 To reduce the transmission of TB to others; 
 To prevent the development and transmission of drug resistant TB. 
   There are more than twenty drugs available for TB treatment. They are used in 
differing combinations in different circumstances. So for example, some TB drugs are 
only used for the treatment of new patients when there is no suggestion of any drug 
resistance. Others are only used for the treatment of drug resistant TB. The new TB 
drugs bedaquiline and delamanid are also now available to be used for the treatment 
of MDR-TB when there aren’t any other drugs available. More than 90% of people with 
drug susceptible TB (that is TB which is not drug resistant) can be cured in six months 
using a combination of “first line” TB drugs. 
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NEED FOR THE NEW ANTI-TB DRUGS 
 The new rise in TB cases and especially the increase of drug resistant 
mycobacteria indicate an urgent need to develop new anti-TB drugs. 
 The long duration of TB therapy is a consequence of persistent mycobacterium 
Tuberculosis, not effectively killed by current anti-TB agents.
[19]
 
 Recent advances in the knowledge of the biology of organism and the availability 
of the genome sequence give an opportunity to explore a wide range of novel 
targets for drug design. 
 There is a need to design new drugs that are more active against slowly growing 
and non-growing persistent bacilli to meet the population at risk of developing 
active disease through reactivation. 
 It is important to achieve a shortened therapy schedule to encourage patient 
compliance and to slow down the development of drug resistance in 
mycobacteria.
[20]
 
 To improve the treatment of MDR-TB.  
 To provide more effective treatment of latent tuberculosis infection. 
 XDR TB disease is resistant to first-line and second-line drugs, patients are left 
with treatment options that are more toxic, more expensive, and much less 
effective.
[21]
  
 Discovery of a compound that would reduce both the total duration of treatment 
and the frequency of drug administration.  
 With multidrug resistant cases of tuberculosis increasing globally, better 
antibiotic drugs and novel drug targets are becoming an urgent need.
[22]
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ENZYME PROFILE 
TARGET: L, D-TRANSPEPTIDASE-2 [23] 
    Transpeptidase may refer to: DD-transpeptidase, a bacterial enzyme that cross-
links the peptidoglycan chains to form rigid cell walls. Peptidyl transferase, which acts as 
an enzyme in ribosomes. Gamma-glutamyl transpeptidase, a liver enzyme .D-glutamyl 
transpeptidase .Sortase, and possibly archaeosortase and exosortase, enzymes involved in 
protein sorting in prokaryotes.
 
 
 Traditional β-lactam antibiotics that inhibit D, D-transpeptidases are not effective 
against mycobacteria, because mycobacteria rely mostly on L, D-trans peptidases 
for biosynthesis and maintenance of their peptidoglycan layer.  
 This reliance plays a major role in drug resistance and persistence of 
Mycobacterium tuberculosis (Mtb) infections.  
 The crystal structure at 1.7 Å resolution of the M -tb L, D-transpeptidase 
containing a bound peptidoglycan fragment, provides information about catalytic 
site organization as well as substrate recognition by the enzyme.  
 Based on structural, kinetics, and calorimetric data, a catalytic mechanism for 
LdtMt2 in which both acyl- acceptor and acyl-donor substrates reach the catalytic 
site from the same, rather than different, entrance has been proposed by Sabri B. 
Erdemli et al.
[44]
  
 This information provides vital insights that facilitate development of drugs 
targeting this validated yet unexploited enzyme. 
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FIGURE 5
[25]
 
 HETEROCYCLIC CHEMISTRY 
              Millions of heterocyclic structures are found to exist having special properties 
and biological importance. Among various compounds, we have chosen 1, 3, 4-
oxadiazole. This ring system possesses important biological activity and many drugs 
contain an oxadiazole ring.  
1, 3, 4- OXADIAZOLE- NUCLEUS
 [26]
 
1, 3, 4-Oxadiazole is a heterocyclic compound containing an oxygen atom and 
two nitrogen atoms in a five- membered ring. It is derived from furan by substitution of 
two methylene groups (=CH) with two pyridine type nitrogens (-N=). 
 
O
N N
O
N
N
O
N
N
O
N N
1,3,4-oxadiazole 1,2,4-oxadiazole 1,2,3-oxadiazole 1,2,5-oxadiazole
 
Isomers of oxadiazole 
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Of these 1, 3, 4-oxadiazole and 1, 2, 4-oxadiazole are better known, and more 
widely studied by researcher because of their many important chemical and biological 
properties. 
OPEN ACCESS 
Among heterocyclic compounds, 1, 3, 4-oxadiazole has become an important 
construction motif for the development of new drugs. Compounds containing 1, 3, 4 -
oxadiazole cores have a broad biological activity spectrum including antibacterial, 
antifungal, analgesic, anti-inflammatory, antiviral, anticancer, antihypertensive, 
anticonvulsant, and anti-diabetic properties. They have also attracted interest in 
medicinal chemistry as surrogates (bioisosteres) for carboxylic acids, esters and 
carboxamides . The ability of 1, 3, 4-oxadiazole heterocyclic compounds to undergo 
various chemical reactions has made them important for molecule planning because of 
their privileged structure, which has enormous biological potential. Two examples of 
compounds containing the 1, 3, 4-oxadiazole unit currently used in clinical medicine are: 
Raltegravir, an antiretroviral drug and Zibotentan an anticancer agent. 
 
The synthesis of novel 1, 3, 4-oxadiazole derivatives, and investigation of their 
chemical properties and biological behavior has accelerated in the last two decades. In 
recent years the number of scientific studies with these compounds has increased 
considerably. Considering the period from 2002 to 2012, the Scifinder Scholar database 
records 2,577 references to 1, 3, 4-oxadiazole, demonstrating its relevance for 
heterocyclic chemistry. Figure 5 shows the number of publications over the past twelve 
years involving 1, 3, 4-oxadiazole. The graph is of course not linear, there is a decrease 
from 2002 (169 articles) to 2003 (146 articles), and then a gradual increase from 2003 to 
2006 (219 articles), again a small decline from 2006 to 2007 (214 articles), and an 
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increase from 2007 to 2011 (319 articles).Taking into account the importance of these 
compounds to both heterocyclic and medicinal chemistry, we have decided to present the 
main synthetic approaches used for obtaining the heterocyclic nucleus, as well as the 
broad spectrum of pharmacological activities reported in the literature over the past 
twelve years. 
 
Figure 6
[26] 
 
Literature survey reveals that among heterocyclic compounds, 1, 3, 4-oxadiazole 
is an important moiety for development of new drugs.  
Compounds containing 1, 3, 4-oxadiazole moiety has been found to exhibit wide 
range of biological activities including 
 Anticancer 
 Antibacterial 
 Antifungal 
 Analgesic 
 Anti-inflammatory 
 Anticonvulsant  
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 1, 3, 4-Oxadiazoles have also gained interest in medicinal chemistry as surrogates 
for carboxylic acids, esters and carboxamides. Because of their privileged structure, 
oxadiazoles possess great biological potential and thus has made them important for 
molecule planning. Variety of therapeutically active compounds currently being used in 
clinical medicine are: HIV – integrase inhibitor Raltegraviran antiretroviral drug 
.Zibotentan an anticancer agent , a nitrofuran antibacterial furamizole , antihypertensive 
agents tiodazosin and nesapidil are based on 1,3,4-Oxadiazole moiety. Since many of 1, 
3, 4-oxadiazoles display a remarkable biological activity, their synthesis and 
transformations have been receiving particular interest for a long time.  
 
In recent years the number of scientific studies with these compounds has increased  
Considerably. Considering the importance of these compounds to both heterocyclic and 
medicinal chemistry, we have decided to discuss the main synthetic approaches used for 
obtaining the oxadiazole moiety, as well as the broad spectrum of pharmacological 
activities reported in the literature.  
It was observed from the literature that certain five membered heterocyclic 
compounds possess interesting biological activity. Among them the compounds bearing 
1, 3, 4-oxadiazole and pyrazole nucleus have wide applications in medicinal chemistry. 
These compounds also have been reported to have significant antitubercular activity. 
 
REVIWE OF LITERATURE 
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REVIEW OF LITERATURE 
       Literature related to synthetic methodologies of scaffolds of interest, Drug Design 
and QSAR methods, target and screening methods for antitubercular activity was 
reviwed. 
1. Robert Koch. (2008) [3] He was the first microbiologist to establish that 
mycobacterium is the cause of tuberculosis. 
 
2. Rahul Jain et al. (2005) [27] Established that tuberculosis is the second leading 
infectious causes of mortality today behind only HIV/AIDS. 
3. Van der Geize R et al. (2007) [15] Worked on the Gene cluster encoding 
cholesterol catabolism a Soil Actinomycetes provides insight into mycobacterium 
tuberculosis survival in Macrophages. 
 
4. Thomas ST et al. (2011) [7] Carried out pathway profiling in mycobacterium 
tuberculosis and elucidation of cholesterol derived catabolite and enzymes that 
catalyze its metabolism. 
 
THE REVIEW OF LITERATURE RELATED TO THE TARGET ENZYME, 
3VYP AND ITS FUNCTION:  
 
5. Kim et al. (2013) [24] worked on the Structural basis for the inhibition of 
Mycobacterium tuberculosis.  
6. Hyoun Sook Kim et al. (2012) [25] reported the structural basis for the inhibition 
of Mycobacterium Tuberculosis. 
A LITERATURE REVIEW OF THE AVAILABLE 1, 3, 4 OXADIAZOLE WAS 
CONDUCTED  
 
7. Patel and Patel et al. (2014) [28] synthesized 5-aryl-2-amino-1, 3, 4-oxadiazole 
compounds  in good yield. 
REVIWE OF LITERATURE 
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8.  Kerimov et al. (2014) [29] synthesized a new series of 2-amino-1, 3, 4-
oxadiazoles 17 carrying a benzimidazole moiety in 33%–60% yield from the 
reaction between 2-(2-(4-substituted-phenyl)-1H-benzo[d]imidazol-1-yl) 
acetohydrazide and cyanogen bromide. 
 
9.  Katritzky et al. (2014) [30] prepared 5-aryl-2-amino-1, 3, 4-oxadiazole 
compounds in excellent yields from the reaction between di(benzotriazol-1-
yl)methanimine and arylhydrazides. 
 
10. El-Sayed  et al. [31] synthesized 5-((naphthalen-2-yloxy)methyl)-Nphenyl-1, 3, 4-
oxadiazol-2-amine 24 in 62% yield, by heating compound 23 in ethanol in the 
presence of sodium hydroxide and iodine in potassium iodide. 
 
11. Sahinet al. (2014)[32] synthesized a series of new derivatives of 5-(1-/2-
naphthyloxymethyl)-1,3,4-oxadiazol-2(3H)-thione (R=SH), 5-(1-/2-
naphthyloxymethyl)-1,3,4-oxadiazole-2-amino (R=NH2), and 5-(1-/2-
naphthyloxymethyl)-1,3,4-oxadiazol-2(3H)- ones (R=OH)  and evaluated their 
antimicrobial activity. All were active against S. aureus, E. coli, P. aeruginosa, C. 
albicans and C. parapsilosis at a minimum concentration of 64–256 mg/mL. 
REVIWE OF LITERATURE 
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12.  Bakal et al. (2014) [33] investigated anti-tubercular activity for a series of 2, 5-
disubstituted oxadiazoles against M. tuberculosis H337Rv. The compound with a 
MIC50 = 0.04 ± 0.01 μM was comparable with Isoniazid. 
 
 
 
 
 
 
 
 
 
13.  Kumar et al. (2014)[34] investigated antibacterial and antifungal activity of 2-(5-
amino-1,3,4-oxadiazol-2-yl)-4-bromophenol , and 5-(3,5-dibromophenyl)-1,3,4-
oxadiazol-2-amine against two strains of Gram-positive bacteria; Streptococcus 
aureus, Bacillus subtilis, two strains of Gram-negative bacteria; Klebsiella 
pneumoniae and Escherichia coli, and two fungal species; Aspergillus Niger and 
C. Pannical. The tests showed activities which were approximately equal to the 
standard drugs of treatment streptomycin and griseofulvin, respectively. 
 
REVIWE OF LITERATURE 
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14. Jayashankar B et al. (2014) [35] synthesized a series of novel ether-linked 
bis(heterocycle)s. All the synthesized compounds were screened for anti-
inflammatory and analgesic activities. Some of them showed excellent anti-
inflammatory and analgesic activities.  
 
 
 
 
 
 
15. Samir Bondock et al. (2014) [36] synthesized a new series of 1, 3, 4-oxadiazole-
based heterocycles.The compounds were screened for their antitumor activity.  
Some synthesized compounds exhibited good anti-tumor activity. 
 
16. Johns et al. (2014) [37] reported antiviral activity (through inhibition of viral DNA 
integration) for new derivatives containing the 1, 3, 4-oxadiazole unit in 
combination with a ring system of 8-hydroxy-1,6-naphthyridine. 
 
17. Bankar et al. (2014) [38] reported Vasorelaxant effect of compound, 4-(3-acetyl-5-
(pyridin-3-yl) - 2, 3-dihydro-1, 3, 4-oxadiazol-2-yl) phenyl acetate in rat aortic 
rings through calcium channel blockage. 
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18. Puthiyapurayil et al. (2014) [39] synthesized a novel series of 1, 3, 4-oxadiazoles 
bearing N- methylpyrazoles. Compounds were tested for their cytotoxic activity 
by MTT assay.  
 
19. Tuma et al. (2014) [40] synthesized and evaluated various 1, 3, 4-oxadiazole 
derivatives as to their ability to inhibit tubulin polymerization and block the 
mitotic division of tumor cells and exhibited potent activity. In vitro studies of this 
compound indicated that at nano-concentrations it interrupted mitotic division in 
breast carcinoma and squamous cell tumors, which included multi-drug resistant 
cells.  
 
 
LITERATURE REVIEW RELATED TO THE ENZYME L, D-
TRANSPEPTIDASE  
20. Wen-Juan Li et al.
 [41]
 worked on the crystal structure of L, D-transpeptidase 
LdtMt2 in complex with meropenem reveals the mechanism of carbapenem 
against Mycobacterium tuberculosis.  
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21. Sabari b erdemli et al. 
[42]
 studied that the traditional β-lactam antibiotics that 
disrupt the D, D-transpeptidases are not effective against mycobacteria. As 
mycobacteria rely mostly on β -lactam insensitive L, D-transpeptidases for 
biosynthesis and maintenance of their peptidoglycan layer. Based on the 
structural, kinetic and calorimetric data, catalytic mechanism for LdtMtb2 has 
been proposed.  
 
22. Lauriane Lecoq et al.
 [43] 
worked on the dynamics Induced by β-Lactam 
Antibiotics in the Active Site of Bacillus subtilis L, D-Transpeptidase.  
 
23. Soumya De et al. 
[44] 
investigated the structural and dynamic basis for the 
unexpected inhibition of peptidoglycan crosslinking L, D-transpeptidases by 
carbapenam antibiotics.  
 
THE REVIEW RELATED TO THE DRUG DESIGN STUDY: 
 
24. Deepak D Borkar, et al. (2012)
 [45]
 performed on the Design and Synthesis of p-
hydroxy benzohydrazide Derivatives for their Antimycobacterial Activity. 
 
25. Andrew Worth et al. (1998)
 [46]
 reported on Distribution, Metabolism and 
Excretion (ADME) properties, which are often important in discriminating 
between the toxicological profiles of parent compounds and their 
metabolites/degradation products.  
 
26. Lipinski CA et al. (2001)
 [47]
 investigated on the experimental and computational 
approaches to estimate solubility and permeability in drug discovery and 
development settings. 
 
27. Lipinski CA. (2004)
 [48]
 escribed a Lead and drug-like compounds and the role of 
fine resolution. 
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LITERATURE RELATED TO THE EVALUATION OF ANTI TUBERCULAR 
ACTIVITY BY MABA WAS REVIWED 
 
28. Jose de Jesus Alba-Romero et al.
 [49]
 applied the Alamar Blue Assay to 
determine the susceptibility to anti-tuberculosis pharmaceuticals. The result 
showed that the MABA test is fast and easy to apply. It is a very reliable method 
of determining the drug susceptibility to pharmaceuticals.  
 
29.  Sephra N Ramprasad et al. 
[50] 
studied the multiple application of Alamar Blue 
as an Indicator of metabolic function and cellular health in cell viability 
Bioassays.  
30. Scott G Franzblau et al
. [51]
 studied MIC determination by MABA. A 
colorimetric, Microplate Based Alamar Blue Assay (MABA) method was used to 
determine the MICs of Isoniazid, Rifampin, Streptomycin and Ethambutol for  
Mycobacterium tuberculosis and the H37Rv strain by using bacterial suspensions 
prepared directly from media. The MABA is a simpe, rapid, low cost, appropriate 
technology which does not require extensive instrumentation and which makes 
use of a nontoxic, temperature stable reagent.  
 
Aim and plan of work 
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AIM AND PLAN OF WORK 
 
 
AIM  
The aim of this project is to develop potential antimycobacterial agents.  
 
OBJECTIVES  
 
The objective of the project is to design and synthesize some compounds 
which will act on L, D Transpeptidase 2 and inhibit the cell wall synthesis of M. 
tuberculosis.  
 
 
THE PLAN OF WORK  
 
 
 Design of L,D Transpeptidase 2 inhibitors by docking studies  
 Insilico Prediction of Drug Likeness and Toxicity  
  Laboratory synthesis of the top G score compounds  
  Characterization of the synthesized compounds by 
 Infrared Spectrometry 
 H1Nuclear Magnetic Resonance Spectroscopy 
 C13Nuclear Magnetic Resonance Spectroscopy 
  Mass Spectrometry 
 
 Determination of In-vitro anti tubercular activity of synthesized 
compounds(MABA) 
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The present study was carried out based on the below flow chart 
 
 
                 Finding the HIT compound 
 
 
                              Identification of the lead compound from the HIT 
 
 
 
               Lead optimization 
 
 
 
             Docking of the molecule to the target protein 
 
 
 
            Top G score compounds were selected 
 
 
 
       Insilico drug likeness and toxicity risk assessment 
 
 
 
 
                Synthesis 
 
 
 
Justification of purity-TLC, GC 
 
 
 
          Characterization – Spectroscopy (IR, NMR, GC- MS, LC-MS) 
 
 
           In -vitro antitubercular activity (MABA) 
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MATERIALS AND METHODS 
DOCKING STUDIES 
DRUG DESIGN 
      Molecules for a particular target can now be designed using a number of commercial 
softwares. The software includes GLIDE
®
 of schrodinger, Autodock
®
 tools and Argus 
lab
®
. Molecules from data base can be docked on to relevant targets by using these 
softwares and determine the energetically more reliable conformations. The molecules 
are refined as ligands and receptor protein as target. 
TYPES 
       There are two major types of drug design.     
 Ligand based drug design 
 Structure based drug design 
1. LIGAND BASED DRUG DESIGN 
       Ligand based drug design relies on knowledge of other molecules that bind to the 
biological target of interest. These molecules may be used to derive a pharmacophore 
model that defines the minimum necessary structural characteristics, a molecule must 
possess in order to bind to the target.
 [53]
 In other words, a model of the biological target 
may be built based on the knowledge of what binds to it, and this model in turn may be 
used to design new molecular entities that interact with the target. Alternatively, a 
quantitative structural activity relationship (QSAR), in which correlation between 
calculated properties of molecules and their experimentally determined biological 
activity, may be derived. These QSAR relationships in turn may be used to predict the 
activity of new analogues. 
MATERIAL AND METHODS 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY Page 27 
 
1. STUCTURE BASED DRUG DESIGN 
         Structure based drug design is a direct approach which relies on knowledge of the 
three dimensional structure of the biological target obtained through methods such as x-
ray crystallography and NMR spectroscopy
 [54].
 If an experimental structure of a target is 
not available, it may be possible to create a homology model of the target based on the 
experimental structure of a related protein. Using the structure of the biological target, 
candidate drugs that are predicted to bind with high affinity and selectivity to the target 
may be designed using interactive and selectivity to the target using interactive graphics 
and the intuition of a medicinal chemist or various automated computational procedures 
to suggest new drug candidates.
 [55]
 
 
COMPUTER-AIDED DRUG DESIGN
 [56]
 
 
Computer-aided drug design uses computational chemistry to discover, enhance 
or study drugs and related biologically active molecules. Molecular mechanics or 
molecular dynamics are most often used to predict the conformation of the small 
molecule and to model conformational changes in the biological target that may occur 
when the small molecule binds to it. 
Molecular mechanics methods may also be used to provide semi-quantitative 
prediction of the binding affinity. Also, knowledge- based scoring function may be used 
to provide binding affinity estimates. 
Drug design with the help of computers may be used at any of the following 
stages of drug discovery: 
1.  Hit identification using virtual screening(structure or ligand- based design) 
2. Hit-to-lead optimization of affinity and selectivity (structure- based design, 
QSAR etc.) 
MATERIAL AND METHODS 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY Page 28 
 
3. Lead optimization: Optimization of other pharmacokinetic properties while 
maintaining affinity. 
            In order to overcome the insufficient prediction of binding affinity calculated by 
recent scoring functions, the protein-ligand interaction and a compound’s 3D structure 
information are used for analysis.
 [57]
  
  
ACTIVE SITE IDENTIFICATION 
     Active site identification is the first step in this program. It analyzes the protein to 
find the binding pocket, derives key interaction sites within the binding pocket, and then 
prepares the necessary data for ligand fragment link. The basic input for this step are the 
3D structure of the protein and a pre docked ligand in PDB format, as well as their 
atomic properties. Both ligand and protein atoms need to be classified and their atomic 
properties should be defined, basically into four types: 
1. Hydrophobic atom: All carbons in hydrocarbon chains are in aromatic groups. 
2. H bond donor: Oxygen and Nitrogen atoms bonded to hydrogen atoms. 
3. H bond acceptor: oxygen sp2 and sp hybridized nitrogen atoms with lone pair of 
electrons. 
4. Polar atom: Oxygen and nitrogen atoms that are neither H bond donor nor H 
bond acceptor, sulfur, phosphorous, halogen, metal, and carbon atoms bonded to 
heteroatoms.
[58]
   
DOCKING  
             
      Docking involves the fitting of a molecule into the target structure in a variety of 
positions, conformations and orientations. Molecular docking is used to predict the 
structure of the intermolecular complex formed between two molecules. The small 
molecule called ligand usually interacts with the protein binding site. There are several 
possible mutual conformations in which binding may occur. These are commonly called 
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binding modes. It also predicts the strength of the binding, the energy of the complex; the 
types of the complex; the types of the signal produced and calculates the binding affinity 
between two molecules using scoring functions. The most interesting case is the type of 
protein-ligand interaction, which has its applications in medicine.
[59]
 
TYPES OF DOCKING 
 Lock And Key or Rigid Docking - In rigid docking, both the internal geometry 
of the receptor and ligand is kept fixed and docking is performed.  
 Induced Fit or Flexible Docking - An enumeration on the rotations of one of the 
molecules (usually smaller one) is performed. Every rotation the surface cell occupancy 
and energy is calculated; later the most optimum pose is selected. 
ARGUS LAB
®
 
          Argus lab
®
 4.0 distributed freely us made available for windows platforms by Planaria 
Software.It is an introductory molecular modeling package for students. The Argus docking 
engine implementry in A.L 4.0 approximates an exhaustive search method with similarities 
to AUTODOCK
® 
and GLIDE
®
. 
          Flexible ligand docking is possible with Argus lab® where the ligand is described as 
torsion tree and grids are constructed that overlay the binding site. The accuracy of the Argus 
lab® docking algorithm takes into account, the key features such as “the nature of binding 
site and the number of rotatable bonds in the ligand.” [58] 
STEPS INVOLVED IN DOCKING 
          Docking is done by using ARGUS LAB® Software. 
1. Protein preparation. 
2. Selection of active site (Q-Site finder). 
3. Ligand Preparation. 
4. Docking Procedure. 
5. Visualization / Interpretation of Docking. 
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1. PROTEIN PREPARATION: 
The following set of operation was carried out for the protein preparation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Q-SITE FINDER 
[59]
 
The following set of operation was carried for the Q-site finder 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
Step: 1 
 Enter protein (pdb) ID in the protein data bank. (1TPY) 
 Go to download files and select pdb as text file. 
  Save the download pdb (text file) to the desktop. 
Step: 2 
 Open Argus lab file Open Import pdb file from the desktop. 
 3D Structure of the protein will appear in the workspace of Argus 
lab. 
 Left side of the screen shows molecular tree view. 
 Open pdb Open ‘residues’ ‘Open misc’ 
 From ‘Misc’ delete the inhibitor and hetero residues [Note: Do 
not delete Co-factor] 
 Open water press shift, select all water molecules and delete. 
 Add hydrogen atoms. 
 Go to Calculation on the toolbar energy by UFF method start. 
 Save the prepared protein as *.agi file format in the desktop. 
Step: 1 
 Open Q-Site finder through online. 
 Upload / Import the PDB format of the Protein. 
 Find all the active site and make a list out of the common amino 
acid residues. 
Step: 2 
 Open residues open Amino acids. 
 Press control and select the amino acids which were listed from 
the Q-Site finder. 
 Make sure that all amino acid residues listed are selected. 
 Right click on the mouse make a group from the selected residues 
give name 
 Binding site Ok. 
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3. LIGAND PREPARATION: 
The operation for the ligand preparation that was followed is given below. 
 
 
 
 
 
 
 
 
 
 
4. DOCKING PROCEDURE 
                 The operation for the ligand preparation that was followed is given below. 
 
 
 
 
 
 
 
 
 
 
5. VISUALIZATION / INTERPRETATION OF DOCKING 
               Molegro Molecular viewer will help in analyzing the energies and interaction of 
the Binding. 
 
 
 
 
 
 
 
 Draw the structure from Chem sketch and save as MDL Mol 
format. 
 Import the ligand into workspace of Argus lab. 
 Clean Geometry Clean Hybridization. 
 Select the ligand, Right click on the mouse Make a group from 
the residues give 
 name ligand Ok. 
 
 Select the set up a Dock Ligand calculation from the toolbar. 
 Argus Dock as the Docking Engine. 
 Dock was selected as calculation type. 
 Flexible for the scoring function. 
 Calculation size. 
 Start docking. 
 Save the Docked protein Ligand complex as Brookhaven pdb 
files (*.pdb). 
 
 View Docking view & Secondary Structure view. 
 View Hydrogen bond interaction. 
 Ligand map Interaction overlay. 
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INSILICO SCREENING OF DRUG LIKENESS
 
 
 
                A drug to be pharmacologically active and exert the action it should possess 
pharmacokinetic properties like absorption, distribution, metabolism and excretion. In 
the field of drug research and development many drug failures occurs due to unfavorable 
ADME properties. This has to be ruled out early in the process of drug discovery. Some 
computational methods have been evolved to investigate the most suitable drug 
molecules before synthesis. Lipinski rule of five it is also known as Pfizer’s rule of five 
is a rule used to evaluate drug likeness. It is used to predict whether a molecule is likely 
to be orally bio-available or not. 
LIPINSKI’S RULE [60] 
Lipinski’s rule is used to predict if a molecule is likely to be orally bioavailable 
or to evaluate drug likeness. The rule was formulated by Christopher A. Lipinski in1997. 
The rule states that for drug likeness the molecule should have the following properties. 
 
 
FIGURE 7 [62] 
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     The designed and docked molecules are screened insilico using Molinspiration®, a 
cheminformatics software to evaluate drug likeness. This tool is quick and easy to use. It 
is software available in online for calculation of important molecular properties such as 
 Log P 
 Polar surface area 
 Number of hydrogen bond donors 
 Number of hydrogen bond acceptors 
As well as prediction of bioactivity score for the most important drug targets 
 GPCR ligands 
 Kinase inhibitors 
 Ion channel inhibitors 
 Nuclear acceptors[62] 
ADME ANALYSIS
 [63]
 
A deeper understanding of the relationships between important ADME 
parameters and molecular structure and properties has been used to develop in silico 
models that allow the early estimation of several ADME properties. Among other 
important issues, prediction of properties that provide information about dose size and 
dose frequency such as oral absorption, bioavailability, brain penetration clearance and 
volume of distribution also needed. 
ABSORPTION 
A Compound crossing a membrane by purely passive diffusion, a reasonable 
permeability estimate can be made using single molecular properties, such as log D 
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(diffusion co-efficient) or hydrogen-bonding capacity. The simple insilico models for 
estimating absorption are based on a single descriptor, such as log P (partition 
coefficient), log D, polar surface area which is a descriptor of hydrogen- bonding 
potential. Different multivariate approaches such as multiple linear regressions, partial 
least squares and artificial neural networks have been used to develop quantitative 
structure-human-intestinal-absorption relationships. 
BIOAVAILABILITY 
Important properties for determining permeability seem to be the size of the 
molecule, as well as its capacity to make hydrogen bonds, its overall liphophilicity and 
possible its shape and flexibility. 
BLOOD-BRAIN BARRIER 
Drugs that act in the CNS need to cross the blood brain barrier (BBB) to reach 
their molecular target, by contrast for drugs with a peripheral target, little or no BBB 
penetration might be required in order to avoid CNS side effects. In order for a drug to 
cross the blood brain barrier (molecule targeted to brain). Rule of thumb says log P values 
should be closer to 2 with a molecular mass of <450 Da and or with a polar surface area 
(PSA) <100 A are likely to possess.  
 
Dermal and Ocular Penetration  
For dermal and ocular route it should satisfy the existing parameters like log P 
(partition coefficient) for aqueous solubility, molecular weight and molecular flexibility.  
 
Metabolism  
   Various in silico approaches exist in evaluating the metabolism namely QSAR 
and 3D QSAR etc. apart from those computational chemists have updated the structural 
details in the data bases and tools for predicting metabolism. Simultaneously it reveals 
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the metabolic information as well as the toxicity related to the molecular fragments by 
which the drug molecule undergoes the metabolism.  
TOXICITY PREDICTION
 [64]
 
Toxicity is one of the major criteria to be considered for a molecule to shine as a 
successful clinical candidate in the pharmaceutical research. The Osiris® property 
explorer is an integral part of Actelion’s in house substance registration system. 
Commercial in silico tools estimates toxicity and provides information by the use of 
QSAR (parameters and descriptors), scientific literatures and to some extent in 
abstracting issues from humans.  
  In silico approaches like OSIRIS® property explorer predicts carcinogenicity, 
mutagenicity, teratogenicity, immune toxicology, irritation, sensitization etc. In addition, 
hepato, neuro and cardio toxicity are evaluated in newly updated in silico tools. 
Prediction results  indicates color coded in which the red color shows high risks with 
undesired effects like mutagenicity or a poor intestinal absorption and green color 
indicates drug-conform behavior. 
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SYNTHETIC METHODOLOGY 
 
SYNTHESIS 
The compounds with top docking score were selected for synthesis as per the 
scheme below. The necessary chemicals of laboratory grade for the synthesis were 
procured from Sigma Aldrich and synthesis was carried out. 
 
SCHEME
 [65]
 
 
N
O NH
NH2
pyridine-4-carbohydrazide
ArCOOH
pocl3 N
N N
O
Ar
-
 
PROCEDURE 
A mixture of 0.01 mole pyridine-4-carbohydrazide and 0.01 mole of aromatic 
acid is dissolved in phosphorus oxychloride and refluxed for 18-22 hr. The reaction 
mixture is slowly poured over crushed ice and kept overnight. The solid mass thus 
separated is filtered, dried, and purified by recrystallization from ethanol.
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REACTANT PROFILE 
                          ISONICOTINIC ACID HYDRAZIDE 
                                               
N
NHO
NH2
pyridine-4-carbohydrazide
 
 Molecular formula- C6H7N3O 
Molecular weight -137.13 
Melting point         -171.4ºC 
Appearance            - Colorless or white crystalline powder 
4-CHLORO BENZOIC ACID 
 
O OH
Cl
4-chlorobenzoic acid
 
Molecular formula- C7H5ClO2 
Molecular weight -156.56 
Melting point         -243ºC 
Appearance            - White powder or coarse crystal 
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BENZOIC ACID 
       
O
OH
benzoic acid
 
Molecular formula- C7H5ClO2 
Molecular weight -156.56 
Melting point         -122.41ºC 
Appearance            -White crystalline needles. 
 
3-CHLOROBENZOIC ACID 
O
OH
Cl
3-chlorobenzoic acid
 
Molecular formula- C7H5ClO2 
Molecular weight -156.56 
Melting point         - 243ºC 
Appearance            - White powder or coarse crystal 
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NICOTINIC ACID 
N
O
OH
pyridine-3-carboxylic acid
 
Molecular formula- C6H5NO2 
Molecular weight -123.11 
Melting point         - 237ºC 
Boiling point          - 238ºC 
Appearance            -white translucent crystals 
 
SALICYLIC ACID 
OH
O
OH
2-hydroxybenzoic acid
 
Molecular formula- C7H6O3 
Molecular weight -138.12 
Melting point         -158.6ºC 
Boiling point          -200ºC 
Appearance            -colorless to white crystals 
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CHARACTERIZATION STUDIES 
 
THIN LAYER CHROMATOGRAPHY
 [66]
  
     Pre-coated silica plates are  used for the TLC .Various mobile phase are used , after 
the trial and error method, Benzene: Acetone in the ratio 3:2  is used to determine the Rf 
value of the synthesized compounds.  
 
IR SPECTROSCOPY [67]   
The IR spectrum of the synthesized compound will be verified for the presence of the 
newly created functional groups and absence of the functional group of the parent 
compounds, involved in the reaction. 
Presence of new functional groups 
 C=N stretching in the region of 1730-1650 cm-1 
 C-O-C stretching  in the region of 1200-1300cm-1 
 
H1 NMR SPECTROSCOPY  
      The proton NMR spectrum will be obtained using BRUKER ADVANCE III 500Hz 
NMR spectrometry using the appropriate solvent i.e. Deuterated Dimethyl Sulphoxide. 
BIOLOGICAL EVALUATION OF ANTI-TUBERCULAR ACTIVITY 
The designed and synthesized molecules need to be screened for their  activity to 
inhibit the growth of the Mycobacterium tuberculosis. There are various high throughput 
assays available for screening of new chemical entities against tuberculosis. They are: 

Resazurin Micro plate Assay (REMA)  
Nitrate Reductase Assay (NRA)  
Micro plate Alamar Blue Assay (MABA)  
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3-(4, 5dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT)  
Middle Brook 7H11 Agar dilution Assay  
Broth Micro dilution Method  
BACTEC system  
Luciferase Reporter Phage Assay  
 
THE ALAMAR BLUE ASSAY
 [50]
 
Alamar Blue monitors the reducing environment of the living cell. The active 
ingredient is resazurin (IUPAC name: 7-hydroxy-10-oxidophenoxazin-10-ium-3-one), 
also known as diazoresorcinol, azoresorcin, resazoin, resazurine, which is water-soluble, 
stable in culture medium, is non-toxic and permeable through cell membranes. 
Continuous monitoring of cells in culture is therefore permitted. Growth is measured 
quantitatively by a visual color change and the amount of fluorescence produced is 
proportional to the number of the living cells which is determined by colorimetric and 
fluorimetric methods. 
ADVANTAGES  
 It has accurate time course measurement. 
 It has high sensitivity and linearity. 
 It involves no cell lysis. 
 
IN VITRO ANTITUBERCULAR ACTIVITY 
 
MICROPLATE ALAMAR BLUE ASSAY (MABA)
 [51]
 
 The anti-mycobacterial activities of the synthesized compounds are determined 
by MABA method. The organism used is M.tuberculosis H37Rv 
 Alamar blue dye is used as an indicator for the determination of viable cells. 
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PRINCIPLE 
MABA is an indirect colorimetric Drug Susceptibility Test method for 
determining the Maximum Inhibitory Concentrations of TB drugs for strains of 
Mycobacterium tuberculosis. In this assay, the redox indicator Alamar blue monitors the 
reducing environment of the living cells. It turns from blue to pink in the presence of 
mycobacterium growth. 
PROCEDURE  
1) The anti-mycobacterium activity of compounds was assessed against M. 
tuberculosis using Micro Plate Alamar Blue assay (MABA).  
2) This methodology is non-toxic, and uses a thermally stable reagent and shows 
good correlation with proportional and BACTEC radiometric method.  
3) 200μl of sterile deionized water is added to all outer perimeter wells of sterile 96 
wells plate to minimize evaporation of medium in the test wells during 
incubation.  
4) The 96 wells plate receives 100 μl of the Middle brook 7H9 broth and serial 
dilution of compounds is placed directly on plate.  
5) The final drug concentrations tested is 100 to 0.8 μg/ml.  
6) Plates are covered and sealed with film and incubated at 37ºC for five days.  
 
7) After this time, 25μl of freshly prepared 1:1 mixture of Alamar Blue reagent and 
10% Tween 80 is added to the plate and incubated for 24 hrs.  
8) A blue color in the well is interpreted as no bacterial growth, and pink color was 
scored as growth.  
 
The MIC is defined as lowest drug concentration which prevents the color change from 
blue to pink.   
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 INSILICO DRUG LIKENESS PROPERTY   
Insilico drug likeness property   is used to predict whether a molecule is likely to 
be orally bio-available or to evaluate drug likeness.This property prediction was  done 
using the software  Molinspiration
®.The output is presented here with SA, NA, VS1, 
VS2, VS4 and VS5. 
CODE: SA 
 
CODE: NA 
 
 
 
RESULTS & DISCUSSION 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY Page 44 
 
 
CODE: VS1 
                   
                                                  
CODE: VS2 
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CODE: VS4 
               
     
CODE:VS5               
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DOCKING 
The derivatives of the selected 100 compounds were docked against 3VYP (Mtb 
enzyme).The molecules were screened for good docking score and interactions. The 
results of the docking for the different compounds are presented below:  
TABLE 1- DOCKING SCORES AND VIEW 
 
 
CODE 
    
CHEMICAL   STRUCTURE 
 
DOCKING 
SCORE 
 
 
                DOCKING VIEW 
 
 
 
VS1 
 
N
N N
O
Cl
4-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]pyridine  
 
 
-9.796 
Kcal/mol 
 
 
 
 
 
 
VS2 
 
 
N
N N
O
4-(5-phenyl-1,3,4-oxadiazol-2-yl)pyridine
 
 
 
-9.672 
Kcal/mol 
 
 
 
 
 
 
VS4 
 
 
N
N N
O
Cl
4-[5-(3-chlorophenyl)-1,3,4-oxadiazol-2-yl]pyridine
 
 
 
 
-9.541 
Kcal/mol 
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 CODE 
 
CHEMICAL   
STRUCTURE 
 
DOCKING 
SCORE 
 
 
DOCKING VIEW 
VS5 
N
N N
O
Cl
 
 
3-[5-(4-chlorophenyl)-
1,3,4-oxadiazol-2-
yl]pyridine 
 
-9.452 
Kcal/mol 
 
 
 
 
 
NA 
N
N N
O
N
4,4'-(1,3,4-oxadiazole-2,5-diyl)dipyridine
 
-8.351 
Kcal/mol 
 
     SA 
 
N
N N
O
OH
2-[5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl]phenol
 
 
-9.310 
Kcal/mol 
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TABLE 2-INTERACTIONS WITH HYDROGEN BOND AND AMINO ACIDS 
 
 
 
CODE HYDROGEN BOND 
INTERACTIONS 
INTERACTION WITH 
AMINO ACIDS 
 
 
 
 
 
VS1 
  
 
       
 
 
 
 
 
 
VS2 
 
 
 
 
 
 
 
 
 
VS4 
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CODE 
HYDROGEN BOND 
INTERACTIONS 
INTERACTION WITH AMINO 
ACIDS 
 
 
 
VS5 
 
 
    
 
 
 
 
 
SA 
      
 
 
 
 
NA 
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TOXICITY PREDICTION (OSIRIS PROPERTY 
EXPLORER) 
           All the data set molecules were subjected to the toxicity risk assessment by using 
Osiris program.Prediction results are color coded in which the red color shows high risks 
with undesired effects like mutagenicity or a poor intestinal absorption and green color 
indicates drug-conform behavior. 
SAMPLE CODE: SA 
 
FIGURE 8- TOXICITY PREDICTION OF SAMPLE SA 
SAMPLE CODE: NA 
 
FIGURE 9- TOXICITY PREDICTION OF SAMPLE NA 
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SAMPLE CODE: VS1 
 
FIGURE 10 - TOXICITY PREDICTION OF SAMPLE VS1 
 
SAMPLE CODE: VS2 
 
FIGURE 11- TOXICITY PREDICTION OF SAMPLE VS2 
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SAMPLE CODE: VS4 
 
FIGURE 12- TOXICITY PREDICTION OF SAMPLE VS4 
 
SAMPLE CODE: VS5 
FIGURE 13- TOXICITY PREDICTION OF SAMPLE VS5 
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PRODUCT PROFILE 
          The synthesized compounds were evaluated for their purity through melting point 
determination and checking absence of parent compounds or other new compounds by 
TLC. The mobile phase used for all the synthesized compounds was benzene: Acetone in 
the ratio of 3:2. The selected 6 scaffolds were synthesized in an appropriate manner and 
recystallized. Then the purity of the compounds was determined by sharp melting point 
and single spot obtained in the TLC. 
TABLE 3 
SAMPLE 
CODE 
MOLECULAR 
WEIGHT 
MELTING 
POINT 
Rf 
VALUE 
YIELD (%) 
SA 239 196ºC 0.71 80% 
NA         224 157 ºC 0.51 72% 
VS1 257 166 ºC 0.61 70% 
VS2 257 92 ºC 0.55 75% 
VS4 257 108 ºC 0.44 82% 
VS5 257 165 ºC 0.53 74% 
           The Rf value of the synthesized compounds was varied from the Rf 
value of the reactants.It is concluded that the reaction was 
completed.The compounds were obtained in acceptable yield. 
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CODE SA 
 
IUPAC NAME:  2-[5-(pyridin-4-yl)-1, 3, 4-oxadiazol-2-yl] phenol 
 
 
N
N N
O
OH
 
 
Molecular Formula       -C13H9N3O2 
Molecular Weight        -239.22 
Appearance                   -Yellow color 
Melting Point                -196
0
C 
Yield -80% 
Composition                 - C (65.27%) H (3.79%) N (17.56%) O (13.38%) 
Molar Refractivity        - 63.89 ± 0.3 cm3 
Molar Volume              - 180.8 ± 3.0 cm3 
Parachor                        -505.4 ± 4.0 cm3 
Index of Refraction      -1.624 ± 0.02 
Surface Tension            -57.8 ± 3.0 dyne/cm 
Density                         - 1.322 ± 0.06 g/cm3 
Polarizability                -25.32 ± 0.5 10- 24 cm3 
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IR SPECTRUM: SA 
 
FIGURE 14- IR SPECTRUM OF SAMPLE SA 
 
TABLE 4- IR INTERPRETATION OF SAMPLE SA 
 
 
 
 
S.No 
 
Wavenumber (cm
-1
) 
 
Functional group 
1. 
2. 
3. 
4 
5. 
3078 cm
-1
 
1257 cm
-1
 
1573 cm
-1
 
1697 cm-1 
3433 cm
-1
 
Ar  C-H stretching 
C-O-C Stretching 
Ar C=C Stretching 
C=N Stretching 
O-H Stretching 
RESULTS & DISCUSSION 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY Page 56 
 
 
GC-MS : SA 
 
 
 
FIGURE 15- GC-MS SPECTRUM OF SAMPLE CODE SA 
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H1NMR SPECTRUM: SA 
 
FIGURE 16-H1 NMR SPECTRUM OF SAMPLE SA 
TABLE 5- H1 NMR INTERPRETATION OF SAMPLE SA 
 
 
 
S.NO 
 
         δ VALUE(PPM) 
 
NATURE OF PEAK 
 
NUMBER OF 
PROTONS 
 
1. 
2. 
3. 
4. 
5. 
6. 
 
2.54-2.55ppm 
7.03-7.17ppm 
7.37-7.53 ppm 
7.96-7.98 ppm 
8.18-8.23 ppm 
8.95-8.96 ppm 
 
 
Singlet 
Triplet 
Triplet 
Doublet 
Doublet 
Doublet 
 
2 
2 
1 
1 
2 
1 
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C13 SPECTRUM OF SA 
 
 
FIGURE 17- C13 SPECTRUM OF SA 
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CODE:   NA 
 
IUPAC NAME:  4, 4'-(1, 3, 4-oxadiazole-2, 5-diyl) dipyridine 
 
 
N
N N
O
N
 
 
Molecular Formula        -C13H8N4O 
Molecular Weight          -224.21 
Appearance                    -Brown color 
Melting Point                 -157
0
C 
Yield -72% 
Composition                  - C (64.10%) H (3.60%) N (24.99%) O (7.14%) 
Molar Refractivity         - 60.10 ± 0.3 cm3 
Molar Volume               - 194.4 ± 3.0 cm3 
Parachor                         -484.5 ± 4.0 cm3 
Index of Refraction       -1.599 ± 0.02 
Surface Tension             -57.8 ± 3.0 dyne/cm 
Density                           - 1.276 ± 0.06 g/cm3 
Polarizability                 -23.82 ± 0.5 10- 24 cm3 
Nominal mass                -224Da 
Monoisotopic mass        -224.04Da 
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IR SPECTRUM: NA 
 
FIGURE 18- IR SPECTRUM OF SAMPLE NA 
 
 
TABLE 6- IR INTERPRETATION OF SAMPLE NA 
 
 
 
S.no 
 
Wavenumber (cm
-1
) 
 
Functional group 
 
1. 
 
2. 
 
3. 
 
4. 
 
3031 cm
-1
 
 
1296 cm
-1
 
 
1596 cm
-1
 
 
               1704 cm-1 
 
Ar  C-H stretching 
 
C-O-C Stretching 
 
Ar C=C Stretching 
 
C=N Stretching 
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GC-MS SPECTRUM: NA 
               
 
 
FIGURE 19- GC-MS SPECTRUM OF SAMPLE NA 
RESULTS & DISCUSSION 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY Page 62 
 
 
H1NMR SPECTRUM: NA 
 
 
FIGURE 20-H1 NMR SPECTRUM OF SAMPLE NA 
 TABLE 7- H1NMR INTERPRETATION OF SAMPLE NA 
 
S.NO 
 
δ VALUE( PPM) 
 
NATURE OF PEAK 
 
NUMBER OF 
PROTONS 
 
1. 
 
2. 
 
3. 
 
4. 
 
5. 
 
7.68-7.71ppm 
 
8.09-8.10ppm 
 
8.52-8.55ppm 
 
8.83-8.89ppm 
 
           9.33-9.34ppm 
 
Quartet 
 
Triplet 
 
Multiplet 
 
Multiplet 
 
Doublet 
 
 
1 
 
2 
 
1 
 
3 
 
1 
RESULTS & DISCUSSION 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY Page 63 
 
 
C13 SPECTRUM OF NA 
 
FIGURE 21- C13 SPECTRUM OF NA 
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CODE:   VS1 
 
 
 
IUPAC NAME: 4-[5-(4-chlorophenyl)-1, 3, 4-oxadiazol-2-yl] pyridine 
 
N
N N
O
Cl
 
 
 
Molecular Formula        -C13H8ClN3O 
Molecular Weight      -257.67 
Appearance                -White color 
Melting Point             -166
0
C  
Yield   -70%    
Composition              - C (60.60%) H (3.13%) Cl (13.76) N (16.31%) O (6.21%) 
Molar Refractivity     - 66.90 ± 0.3 cm
3
 
Molar Volume           -194.4 ± 3.0 cm
3
 
Parachor                     -526.2 ± 4.0 cm
3
 
Index of Refraction    -1.604 ± 0.02 
Surface Tension          -53.6 ± 3.0 dyne/cm 
Density                        - 1.325 ± 0.06 g/cm
3
 
Polarizability               -26.52 ±0.5 10- 24 cm
3 
Nominal mass            -257Da 
Monoisotopic mass   -257.033Da 
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IR SPECTRUM: VS1 
FIGURE 22- IR SPECTRUM OF SAMPLE VS1 
TABLE 8- IR INTERPRETATION OF SAMPLE VS1 
 
 
 
 
 
S.no 
 
Wavenumber (cm
-1
) 
 
Functional group 
 
1. 
 
2. 
 
3. 
 
4. 
 
5. 
 
3055 cm
-1
 
 
1288 cm
-1
 
 
1596 cm
-1
 
 
1689 cm-1 
 
753cm
-1
 
 
Ar  C-H stretching 
 
C-O-C Stretching 
 
Ar C=C Stretching 
 
C=N Stretching 
 
C-Cl Stretching 
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LC-MS SPECTRUM: VS1 
 
FIGURE 23- LC-MS SPECTRUM OF SAMPLE VS1 
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H
1
NMR SPECTRUM: VS1 
 
FIGURE 24- H1 NMR SPECTRUM OF SAMPLE VS1 
TABLE 9- H1NMR INTERPRETATION OF SAMPLE VS1 
 
 
 
S.NO 
 
δ VALUE(PPM) 
 
NATURE OF PEAK 
 
NUMBER OF 
PROTONS 
 
1. 
 
2. 
 
3. 
 
4. 
 
5. 
 
          7.62-7.64ppm 
 
          7.77-7.81ppm 
 
  7.98-7.8.01ppm 
 
8.15-8.26ppm 
 
           8.93-8.95ppm 
 
Doublet 
 
Doublet 
 
Doublet 
 
Doublet 
 
Doublet 
 
2 
 
1 
 
2 
 
2 
 
 1 
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C13NMR SPECTUM: VS1               
 
FIGURE 25-C13 NMR SPECTRUM OF SAMPLE VS1 
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CODE:   VS2 
 
IUPAC NAME:                   4-(5-phenyl-1, 3, 4-oxadiazol-2-yl) pyridine 
 
N
N N
O
 
 
 
Molecular Formula         -C13H9N3O 
Molecular Weight           -223.23 
Appearance                      - White color 
Melting Point                   -92
0
C  
Yield     -75%    
Composition                    - C (69.95%) H (4.06%) N (18.82%) O (7.17%) 
Molar Refractivity          - 62.01 ± 0.3 cm3 
Molar Volume                - 182.4 ± 3.0 cm3 
Parachor                          -490.4 ± 4.0 cm3 
Index of Refraction        -1.595 ± 0.02 
Surface Tension             -52.1 ± 3.0 dyne/cm 
Density                            - 1.223 ± 0.06 g/cm3 
Polarizability                   -26.52 ±0.5 10- 24 cm3 
Nominal mass             -223Da 
Monoisotopic mass   - 223.03Da 
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IR SPECTRUM: VS2 
 
FIGURE 26- IR SPECTRUM OF SAMPLE VS2 
 
 
TABLE 10- IR INTERPRETATION OF SAMPLE VS2 
 
 
 
 
 
S.no 
  
Wave number (cm
-1
) 
 
Functional group 
       
1. 
 
2. 
 
3. 
 
4. 
 
3062  cm
-1
 
 
1288 cm
-1
 
 
1542 cm
-1
 
 
1606 cm-1 
 
 
Ar  C-H stretching 
 
C-O-C Stretching 
 
Ar C=C Stretching 
 
C=N Stretching 
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LC-MS SPECTRUM: VS2 
 
 
FIGURE 27- IR SPECTRUM OF SAMPLE VS2 
 
 
RESULTS & DISCUSSION 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY Page 72 
 
 
H
1
NMRSPECTRUM: VS2 
 
 
FIGURE 28- H1 NMR SPECTRUM OF SAMPLE VS4 
 
TABLE 11-H1 NMR INTERPRETATION OF SAMPLE VS4 
 
S.NO 
 
δ VALUE 
 
NATURE OF PEAK 
 
NUMBER OF 
PROTONS 
 
1. 
 
2. 
 
3. 
 
4. 
 
 
7.53-7.57ppm 
 
7.65-7.73ppm 
 
  7.98-7.8.01ppm 
 
8.18-8.2ppm 
 
 
Triplet 
 
Multiplet 
 
Triplet 
 
Triplet 
 
1 
 
4 
 
2 
 
2 
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C13 NMR SPECTRUM: VS2 
 
 
FIGURE 29- C13 NMR SPECTRUM OF SAMPLE VS2 
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CODE:   VS4 
 
IUPAC NAME:   4-[5-(3-chlorophenyl)-1, 3, 4-oxadiazol-2-yl] pyridine 
 
N
O
N
N
Cl
 
 
 
Molecular Formula           -C13H8ClN3O 
Molecular Weight            -257.67 
Appearance                             - White color 
Melting Point                   -108
0
C  
Yield        -82%    
Composition                   - C (60.60%) H (3.13%) Cl (13.76) N (16.31%) O (6.21%) 
Molar Refractivity          - 66.90 ± 0.3 cm3 
Molar Volume                - 194.4 ± 3.0 cm3 
Parachor                          -526.2 ± 4.0 cm3 
Index of Refraction        -1.604 ± 0.02 
Surface Tension              -53.6 ± 3.0 dyne/cm 
Density                           - 1.325 ± 0.06 g/cm3 
Polarizability                  -26.52 ±0.5 10- 24 cm3 
Nominal mass   -257Da 
Monoisotopic mass       -257.033Da 
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IR SPECTRUM: VS4 
 
 
FIGURE 30- IR SPECTRUM OF SAMPLE VS4 
 
TABLE 12- IR INTERPRETATION OF SAMPLE VS4 
 
 
 
S.no 
 
Wavenumber (cm
-1
) 
 
Functional group 
1. 
2. 
3. 
4. 
5. 
 
3078 cm
-1
 
1257 cm
-1
 
1573 cm
-1
 
1697 cm-1 
748cm
-1
 
 
Ar  C-H stretching 
C-O-C Stretching 
Ar C=C Stretching 
C=N Stretching 
C-Cl Stretching 
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GC-MS SPECTRUM: VS4 
 
 
 
FIGURE 31- GC-MS SPECTRUM OF SAMPLE VS4 
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H
1
NMR SPECTRUM:  VS4 
 
FIFURE 32- H1 NMR SPECTRUM OF SAMPLE VS4 
 
TABLE 13- H1 INTERPRETATION OF SAMPLE VS4 
 
 
S.NO 
 
δ VALUE 
 
NATURE OF PEAK 
 
NUMBER OF 
PROTONS 
 
1. 
 
2. 
 
3. 
 
7.53-7.57 
 
7.89-7.91 
 
8.88-8.89 
 
 
Triplet 
 
Multiplet 
 
Doublet 
 
3 
 
4 
 
2 
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C
13
NMR SPECTRUM: VS4 
 
 
FIGURE 33- C13 NMR SPECTRUM OF SAMPLE VS4 
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CODE:   VS5 
  
 
IUPAC NAME:                       3-[5-(4-chlorophenyl)-1, 3, 4-oxadiazol-2-yl] pyridine 
 
N
O
N
N
Cl
 
 
Molecular Formula           -C13H8ClN3O 
Molecular Weight             -257.67 
Appearance                       -White color 
Melting Point                    -165
0
C 
Yield     -74% 
Composition                     - C (60.60%) H (3.13%) Cl (13.76) N (16.31%) O (6.21%) 
Molar Refractivity             - 66.90 ± 0.3 cm3 
Molar Volume                  - 194.4 ± 3.0 cm3 
Parachor                           -526.2 ± 4.0 cm3 
Index of Refraction           - 1.604 ± 0.02 
Surface Tension                -53.6 ± 3.0 dyne/cm 
Density                            - 1.325 ± 0.06 g/cm3 
Polarizability                   -26.52 ±0.5 10- 24 cm3 
Nominal mass      -257Da 
Monoisotopic mass           -257.033Da 
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IR SPECTRUM: VS5 
 
 
FIGURE 34- IR SPECTRUM OF SAMPLE VS5 
 
TABLE 14- IR INTERPRETATION OF SAMPLE VS5 
 
 
 
S.No 
 
Wavenumber (cm
-1
) 
 
Functional group 
 
1. 
2. 
3. 
4. 
5. 
 
3055 cm
-1
 
1288 cm
-1
 
1596 cm
-1
 
1689 cm-1 
753cm
-1 
 
Ar  C-H stretching 
C-O-C Stretching 
Ar C=C Stretching 
C=N Stretching 
C-Cl Stretching 
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GC-MS SPECTRUM: VS5 
 
 
 
 
FIGURE 35- GC-MS SPECTRUM OF SAMPLE VS5 
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H
1
NMR SPECTRUM: VS5        
     
 
FIGURE 36- H1 NMR SPECTRUM OF SAMPLE VS5 
TABLE 15- HI INTERPRETATION OF SAMPLE VS5 
 
S.NO 
 
δ VALUE(PPM) 
 
NATURE OF PEAK 
 
NUMBER OF 
PROTONS 
 
1. 
 
2. 
 
3. 
 
4. 
 
 
6.64-6.66ppm 
 
7.17-7.40ppm 
 
7.87-8.00ppm 
 
8.77-8.85ppm 
 
Doublet 
 
Multiplet 
 
Multiplet 
 
                     Multiplet 
 
1 
 
2 
 
3 
 
                   2 
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C
13
NMR SPECTRUM: VS5 
 
 
FIGURE 37-C13 NMR SPECTRUM OF SAMPLE VS5 
 
 
 
 
 
 
 
 
 
 
 
RESULTS & DISCUSSION 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY Page 84 
 
 
MOLECULAR MASS OF THE SYNTHESIZED COMPOUNDS 
TABLE 16- MOLECULAR MASS OF THE SYNTHESIZED COMPOUNDS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAMPLE CODE CALCULATED MASS ACTUAL MASS 
 
SA 
 
 
239.18 g/mole 
 
239.22 g/mole 
 
NA 
 
 
224.09g/mole 
 
224.21 g/mole 
 
VS1 
 
 
257.20 g/mole 
 
257.67 g/mole 
 
VS2 
 
 
223.09 g/mole 
 
223.23 g/mole 
 
VS4 
 
 
257.15 g/mole 
 
257.67 g/mole 
 
                VS5 
 
 
257.08 g/mole 
 
257.67 g/mole 
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ANTI-TB RESULTS 
The recrystallized compounds were screened for Anti-mycobacterial activity in vitro 
method called Microplate Alamar Blue Assay (MABA). The results are tabulated below: 
TABLE 17-ANTI-TB RESULTS 
 
S.NO 
SAMPLE     
CODE 
  100 
µg/ml 
  50 
µg/ml 
   25 
µg/ml 
  12.5 
µg/ml 
  6.25 
µg/ml 
  3.12 
µg/ml 
   1.6 
µg/ml 
   0.8 
µg/ml 
 
1 
 
VS1 
 
S 
 
S 
 
S 
 
R 
 
R 
 
R 
 
R 
 
 R 
 
2 
 
VS2 
 
S 
 
S 
 
S 
 
R 
 
R 
 
R 
 
R 
 
 R 
 
3 
 
VS4 
 
S 
 
S 
 
S 
 
S 
 
R 
 
R 
 
R 
 
 R 
 
4 
 
VS5 
 
S 
 
S 
 
S 
 
S 
 
R 
 
R 
 
R 
 
 R 
 
5 
 
SA 
 
S 
 
S 
 
S 
 
S 
 
R 
 
R 
 
R 
 
 R 
 
6 
 
NA 
 
S 
 
R 
 
R 
 
R 
 
R 
 
R 
 
R 
 
 R 
 
None of the compounds was found to be as sensitive as the standard compounds. 
However the docking score for Pyrazinamide is -6.6Kcal/mol which is higher than that 
all the synthesized compounds. This is a way indicates the limitation of the software. It 
must also be mentioned that compounds with the lowest energetic i.e. VS4, VS5 and SA 
have shown to be more active than the compounds which are energetically less stable.  
NOTE: 
S-Sensitive 
R-Resistant 
Stain used: M. tuberculosis (H37 RV Strain): ATTCC No- 27294 
Here are the standard values for the Anti-Tb test which was performed. 
Pyrazinamide- 3.125 µg/ml 
Streptomycin- 6.25 µg/ml 
Ciprofloxacin- 3.125 µg/ml 
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SAMPLE DRUG PHOTOGRAPH: 
 
 
FIGURE 38- SAMPLE DRUG PHOTOGRAPH 
 
STANDARD DRUG PHOTOGRAPH:
 
FIGURE 39- STANDARD DRUG PHOTOGRAPH 
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MOLECULES DOCKED AGAINST DIFFERENT TARGETS 
The compounds were also docked against other critical enzyme of the 
mycobacterium tuberculosis Diaminopimelate epimarase (dapF) and Glutamine 
synthetase. The docking scores are listed below. 
TABLE 18 
 
SAMPLE 
CODE 
 
L,D 
TRANSPEPTIDASE 2 
 
DIAMINOPIMELATE 
EPIMERASE 
 
GLUTAMINE 
SYNTHETASE 
SA -9.310Kcal/mol -8.262 Kcal/mol -8.926 Kcal/mol 
NA -8.351Kcal/mol -8.212 Kcal/mol -9.121 Kcal/mol 
VS1 -9.796Kcal/mol -9.525 Kcal/mol -9.421 Kcal/mol 
VS2 -9.672Kcal/mol -9.321 Kcal/mol -8.924 Kcal/mol 
VS4 -9.541Kcal/mol -9.528 Kcal/mol -9.121 Kcal/mol 
VS5 -9.452Kcal/mol -9.312 Kcal/mol -8.731 Kcal/mol 
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SUMMARY AND CONCLUSION  
 L, D-Transpeptidase-2 (3VYP) is a critical enzyme for the cell wall synthesis of 
Mycobacterium tuberculosis was chosen for study after review of literature.  
 Selected molecules were designed and docked against L, D-Transpeptidase-2 
(3VYP) using Argus lab® 4.0software. 
 Molecules with good Docking score (lower binding energy) and interactions 
were shortlisted for synthesis. The reaction conditions were optimized.  
 The selected molecules were subjected to Toxicity prediction assessments by 
OSIRIS
® 
software. The results are color coded as green color which predicts the 
drug likeness.  
 Compounds were synthesized by conventional method and labeled as SA, NA, 
VS1, VS2, VS4 and VS5. 
 The purity of the synthesized compounds was ensured by repeated 
recrystallization. Further the compounds were evaluated by TLC and Melting 
point determination.  
 The characterization of the synthesized compounds was done using Infra-red, 
Nuclear Magnetic Resonance (H
1
 NMR &C
13
NMR) and Mass spectroscopic 
methods (LC-MS, GC-MS)  
 The pure compounds were screened for In-vitro Anti- tubercular activity by 
Micro plate Alamar Blue Assay (MABA). All compounds showed a significant 
anti-mycobacterium activity. 
 Docking with other critical enzyme was carried out. 
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CONCLUSION  
 Our work concludes that our synthesized molecules are effective in inhibiting the 
target enzyme L, D-Transpeptidase 2, which is important for the growth of 
Mycobacterium tuberculosis Cell wall.  
  All the 6 compounds gave Docking score between -8.30 to -9.74kcal/mol. There 
is correlation between the score and activities of all the 6 compounds which were 
tested and compared with the standard drugs. 
 Multi target docking was done for different critical enzymes of mycobacterium 
tuberculosis using Argus lab
®.
From the results, the targeted enzyme l,d-
transpeptidase 2 score was closer to the other two target ie., diaminopimelate 
epimerase and glutamine synthase. There was not much significant difference 
between the other two targeted compounds.  
 The minimum inhibitory concentration of the 6 synthesized compounds against 
H37RV ranged from 12.5 μg/ml which is better compared to that of the certain 
known Anti-TB agents. Pyrazinamide- 3.125μg/ml, Ciprofloxacin- 3.125μg/ml 
and Streptomycin- 6.25μg/ml. Further structural refinement to the structure of the 
synthesized compounds is expected to yield promising molecules against the 
pathogen Mycobacterium tuberculosis.  
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